Edge Therapeutics, Inc. (NASDAQ:EDGE) insider Albert N. Marchio II sold 3,361 shares of the company’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $10.00, for a total value of $33,610.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Edge Therapeutics, Inc. (NASDAQ:EDGE) traded up $0.14 during mid-day trading on Friday, hitting $10.04. The stock had a trading volume of 16,882 shares, compared to its average volume of 63,227. Edge Therapeutics, Inc. has a 52 week low of $7.30 and a 52 week high of $13.50. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 8.34.

Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.11. analysts forecast that Edge Therapeutics, Inc. will post -1.7 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its position in Edge Therapeutics by 1.7% during the 1st quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 200 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Edge Therapeutics by 0.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 75,279 shares of the biotechnology company’s stock worth $773,000 after buying an additional 532 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Edge Therapeutics by 16.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,733 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Edge Therapeutics by 7.7% during the 2nd quarter. California State Teachers Retirement System now owns 35,167 shares of the biotechnology company’s stock worth $361,000 after buying an additional 2,500 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Edge Therapeutics by 19.1% during the 2nd quarter. Rhumbline Advisers now owns 19,960 shares of the biotechnology company’s stock worth $205,000 after buying an additional 3,195 shares in the last quarter. Institutional investors and hedge funds own 50.53% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, November 6th. BidaskClub upgraded Edge Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 3rd.

COPYRIGHT VIOLATION WARNING: “Edge Therapeutics, Inc. (EDGE) Insider Albert N. Marchio II Sells 3,361 Shares” was posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/edge-therapeutics-inc-edge-insider-albert-n-marchio-ii-sells-3361-shares/1724758.html.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.